← Oncology Approval Tracker

FDA DECISION ·

Filkri

filgrastim-laha · Accord BioPharma

Biosimilar approvalBiosimilarChemotherapy-associated neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Neupogen biosimilar with labeled cancer uses including febrile-neutropenia risk reduction during myelosuppressive chemotherapy, recovery after AML chemotherapy, and neutropenia support after myeloablative therapy followed by bone marrow transplant.

LAMPGEN ANALYSIS

Why it matters

The approval adds a short-acting growth-factor option across several oncology care settings. Product availability and regimen timing matter for access.

What research teams should watch

Check the labeled indication and route, then match chemotherapy and transplant timing to the supportive-care order. Capture the exact product for safety follow-up.

PRIMARY RECORDS

Sources